Innovation “Crisis” And Health Care Reform: Lilly CEO Urges Change In Focus
This article was originally published in The Pink Sheet Daily
Executive Summary
Lechleiter editorial, Chamber of Commerce appearance include warnings about adverse effects on innovation; “Odyssey Project” launched to press similar themes.
You may also be interested in...
Pharma Share Of Health Reform Cost Savings To Come From Drug Access, Compliance, Personalized Medicine
As stakeholders pledge to reduce health system growth by $2 trillion over 10 years, Rep. Dingell urges support for public plan; Sen. Grassley wants more “concrete” proposals, CBO score.
Medicare Aduhelm Coverage Policy Overrules FDA: Can Two Wrongs Make A Right?
Plenty of people believe the US FDA should never have approved Biogen/Eisai’s Alzheimer’s therapy. But does that really mean it is okay for the Medicare agency to decide as a matter of policy that the drug has not been proven safe and effective?
2022: The End Of The US Price Negotiation Debate?
The Democratic party has been advocating for Medicare drug price negotiation authority in the US for almost two decades. The coming year may see it finally happen – or it might mean the issue is gone for good.